STANFORD UNIVERSITY

Wayne State scientists develop AI models to reduce drug design costs, focusing on complex drug types. Stanford research shows ChatGPT-4 achieving 92% medical diagnostic accuracy, outperforming human doctors. Health tech stocks rose 12% in 2024, with AI healthcare companies attracting 38% of venture capital investments.

GLP-1 agonists, initially for weight loss and diabetes, show potential in treating obstructive sleep apnea (OSA) in obese patients. Clinical trials like SURMOUNT-OSA suggest significant AHI reduction and cardiovascular risk improvement. However, challenges include supply issues, high costs, and the need for comprehensive patient evaluation and lifestyle management.

New blood tests for colon cancer screening are less effective than colonoscopy, with 2.5 times more deaths expected. Colonoscopy remains the most effective method, preventing cancer by removing precancerous polyps. Blood tests, though promising, are not yet covered by guidelines and may worsen outcomes if widely adopted.

The 2024 NFCR Global Summit and Award Ceremonies for Cancer Research & Entrepreneurship, co-hosted with the AIM-HI Accelerator Fund, convened top experts across cancer research, biotech entrepreneurship, pharmaceuticals, investment, and patient advocacy at the National Press Club. The event highlighted cutting-edge cancer research advancements, early detection and intervention, AI in diagnostics and personalized treatment strategies, fostering innovative collaborations, and driving breakthrough solutions. Keynotes and panels discussed immunotherapies, biomarkers, personalized approaches, and AI-powered diagnostics. The summit also featured an Innovative Oncology Company Showcase and investor perspectives, culminating in awards and a panel on the future of cancer research.

Lynden A. Archer reappointed as Joseph Silbert Dean of Engineering at Cornell, effective July 1, 2025. Under his leadership, Cornell Engineering has advanced in research, innovation, and education, focusing on areas like material science, climate, and energy systems. Archer's strategic plan, Cornell Engineering 2030, aims to position the college as a leader in engineering education and research. Notable achievements include the establishment of the Selander Center for Engineering Leadership and significant infrastructure improvements.

A randomized clinical trial involving 50 physicians found that using a large language model (LLM) did not significantly improve diagnostic reasoning performance compared to conventional resources. The LLM alone outperformed both physician groups, indicating a need for further development in human-computer interactions to effectively integrate LLMs into clinical practice.

Aging increases disease risk; targeting the aging process itself could reduce this burden. Researchers are developing 'aging clocks' to measure biological age and 'speedometers' to track aging rates. Blood from young mice rejuvenates aged mice's brains, suggesting potential treatments for neurodegeneration. Calorie restriction (CR) in humans slows biological aging and improves muscle health, though practical measures like physical activity and healthy eating are currently the best anti-aging strategies.

Study estimates HCC incidence in SLD patients, finding higher rates in males, older individuals, those with cirrhosis, DM, CKD, CVD, and non-liver cancer. Incidence rises with age, male sex, cirrhosis, and DM, peaking at 19.06/1,000 PY in males >70 with cirrhosis and DM. Lowest risk is in noncirrhotic, nondiabetic patients <40. Results suggest tailored surveillance strategies based on multiple risk factors.

Stanford Medicine’s Spectrum receives $70M NIH grant to accelerate biomedical treatment translation, led by Ruth O’Hara, aiming to improve patient care and population health. The grant, spanning until 2031, supports collaborative research with Kaiser Permanente and the University of Hawaii, and training for future investigators.

Surbhi Sidana discusses minimal residual disease (MRD) in multiple myeloma, explaining its role in detecting undetectable disease remnants post-treatment, influencing future treatment decisions, and its potential as a surrogate end point for drug approval.